Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of AP30663 in healthy male volunteers
NL-OMON29359Phase 1Recruiting
- Sponsor
- Acesion Pharma
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AP30663 in Atrial fibrillation (AFib), sponsored by Acesion Pharma. Primary endpoints: Treatment-related adverse events, Vital signs and temperature changes and 11 more. Started Feb 2018; status: recruiting.
02
Drugs
AP30663
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON29359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29359.